7. Boston Scientific Corporation (NYSE:BSX)
Number of Hedge Fund Holders as of Q4: 96
Marshall Wace LLP’s Equity Stake: $791.90 Million
With a market capitalization of $154.8 billion, Boston Scientific Corporation (NYSE:BSX) is a leader in medical innovation, specializing in the development and commercialization of advanced medical devices. Based in Marlborough, Massachusetts, the company offers solutions across multiple interventional medical fields, addressing cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions.
In its fiscal fourth-quarter earnings report on February 5, 2025, Boston Scientific Corporation (NYSE:BSX) posted a 22.4% year-over-year revenue increase to $4.6 billion, driven by strong performance across its business segments. Net income increased by 12% to $566 million, while operating profit rose 28% to $790 million, highlighting improved efficiency and profitability. Adjusted earnings per share rose 26% to $0.70, exceeding expectations of $0.66. The cardiovascular segment, led by the success of the Farapulse system, grew nearly 29% to $2.94 billion, while the medical-surgical division reported a 12% revenue increase.
Looking ahead, Boston Scientific Corporation (NYSE:BSX) anticipates 10-12% organic sales growth in 2025, with adjusted earnings per share expected to range between $2.80 and $2.87 and first-quarter adjusted EPS projected between $0.66 and $0.68. This optimistic outlook reinforces its strong market position and continued expansion. Analysts remain highly bullish on Boston Scientific Corporation (NYSE:BSX), assigning it a “Strong Buy” rating. The stock’s mean price target of $118.53 represents a 14.4% upside from current levels, reflecting confidence in its growth trajectory and sustained innovation in medical technology. The company’s strategic investments, operational efficiencies, and ability to navigate economic headwinds position it well for sustained success in the medical device industry.
Investor interest in Boston Scientific Corporation (NYSE:BSX) has been on the rise, with Marshall Wace LLP holding over 8.8 million shares valued at nearly $792 million by the end of Q4 2024, representing 0.95% of its portfolio. Additionally, hedge fund participation increased, as 96 of the 1,009 hedge funds tracked by Insider Monkey had stakes in the company in Q4 2024, collectively valued at nearly $7.22 billion, up from 92 funds in the previous quarter. This surge in institutional investment underscores strong confidence in the company’s growth prospects and reinforces its position as a favored stock among investors.
Baron Health Care Fund stated the following regarding Boston Scientific Corporation (NYSE:BSX) in its Q4 2024 investor letter:
“Boston Scientific Corporation (NYSE:BSX) is a global manufacturer of devices used in a broad range of interventional medical specialties. Shares climbed steadily throughout the quarter on solid company fundamentals, including a double-digit EPS growth profile and cost discipline that produces more than 50 basis points of annual operating margin expansion. We believe Boston Scientific can see sustainable organic growth in the high single digits, driven by differentiated products in electrophysiology and structural heart, in particular, the emerging field of pulsed field ablation (PFA), where the company is well positioned. Temperature-based methods (either hot or cold) to disable heart tissue responsible for irregular heartbeats can damage surrounding tissue. PFA relies on electricity to damage aberrant tissue, and because different types of tissue have different electrical thresholds, the surrounding tissue can be selectively spared. In our opinion, Boston Scientific is a compelling name within the large-cap medical device universe.”
